10-K Filing

Xenetic Biosciences, Inc. CIK: 1534525 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001683168-24-001594`
Period End Date	20231231
Filing Date	20240321
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	xenetic_i10k-123123_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 45 Income Statement 28 Cash Flow Statement 36 Stockholders Equity 14

Balance Sheet 45 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$8.98M	USD	Point-in-time
Cash	`Cash`	$13.10M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$603.83K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$556.09K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.65M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.59M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	10.00M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.07M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	10.00M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.02M	USD	Point-in-time
Common stock, shares, issued	`CommonStockSharesIssued`	1.52M	shares	Point-in-time
Total assets	`Assets`	$14.72M	USD	Point-in-time
Total assets	`Assets`	$10.61M	USD	Point-in-time
Common stock, shares, issued	`CommonStockSharesIssued`	1.54M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	1.52M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	1.54M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$240.83K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$287.36K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$568.75K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$785.80K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$809.59K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.07M	USD	Point-in-time
Total liabilities	`Liabilities`	$809.59K	USD	Point-in-time
Total liabilities	`Liabilities`	$1.07M	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 1,543,385 and 1,519,360 shares issued as of December 31, 2023 and December 31, 2022, respectively; 1,540,684 and 1,516,659 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	`CommonStockValue`	$1.54K	USD	Point-in-time
Common stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 1,543,385 and 1,519,360 shares issued as of December 31, 2023 and December 31, 2022, respectively; 1,540,684 and 1,516,659 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	`CommonStockValue`	$1.52K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$207.77M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$208.05M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-193.23M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-189.10M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Treasury stock	`TreasuryStockCommonValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockCommonValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$18.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$13.65M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.80M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$14.72M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$10.61M	USD	Point-in-time

Income Statement 28 line items

Line Item	Tag	Value	Unit	Period
Basic net loss per share	`EarningsPerShareBasic`	$-2.71	USD	Annual
Basic net loss per share	`EarningsPerShareBasic`	$-4.61	USD	Annual
Diluted net loss per share	`EarningsPerShareDiluted`	$-2.71	USD	Annual
Diluted net loss per share	`EarningsPerShareDiluted`	$-4.61	USD	Annual
Royalty revenue	`RoyaltyIncomeNonoperating`	$1.71M	USD	Annual
Royalty revenue	`RoyaltyIncomeNonoperating`	$2.54M	USD	Annual
Weighted-average shares of common stock outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.53M	shares	Annual
Total revenue	`Revenues`	$2.54M	USD	Annual
Total revenue	`Revenues`	$1.71M	USD	Annual
Weighted-average shares of common stock outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.42M	shares	Annual
Weighted-average shares of common stock outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.53M	shares	Annual
Weighted-average shares of common stock outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.42M	shares	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.49M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$4.77M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.65M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.56M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$7.06M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$8.42M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-6.72M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-4.52M	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-1.60K	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$25.38K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$355.76K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$167.15K	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$165.56K	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$381.14K	USD	Annual
Net loss	`NetIncomeLoss`	$-6.55M	USD	Annual
Net loss	`NetIncomeLoss`	$-4.13M	USD	Annual

Cash Flow Statement 36 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-6.55M	USD	Annual
Net loss	`NetIncomeLoss`	$-4.13M	USD	Annual
Acquired in-process research and development	`ResearchAndDevelopmentsInProcess`	$1.79M	USD	Annual
Acquired in-process research and development	`ResearchAndDevelopmentsInProcess`	-	USD	Annual
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	-	USD	Annual
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$27.04K	USD	Annual
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$511.48K	USD	Annual
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$283.08K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInAccountsAndOtherReceivables`	$103.74K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInAccountsAndOtherReceivables`	$47.73K	USD	Annual
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-48.58K	USD	Annual
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-25.00K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-263.57K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-347.95K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.11M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.65M	USD	Annual
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$500.00K	USD	Annual
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-500.00K	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-4.11M	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-5.15M	USD	Annual
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.98M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.10M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.98M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.10M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	$1.29M	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	-	USD	Annual
Issuance of common stock to adjust for Reverse Stock Split	`IssuanceOfCommonStockToAdjustForReverseStockSplit`	-	USD	Annual
Issuance of common stock to adjust for Reverse Stock Split	`IssuanceOfCommonStockToAdjustForReverseStockSplit`	$16.00	USD	Annual
Conversion of Series A preferred stock to common stock	`ConversionOfSeriesPreferredStockToCommonStock`	-	USD	Annual
Conversion of Series A preferred stock to common stock	`ConversionOfSeriesPreferredStockToCommonStock`	$970.00	USD	Annual

Stockholders Equity 14 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$13.65M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$9.80M	USD	Point-in-time
Issuance of common stock to adjust for reverse split rounding	`IssuanceOfCommonStockToAdjustForReverseSplitRounding`	-	USD	Annual
Conversion of Series A preferred stock to shares of common stock	`ConversionOfSeriesPreferredStockToSharesOfCommonStock`	-	USD	Annual
Issuance of common stock in connection with purchase of in-process research and development	`StockIssuedDuringPeriodValueReverseStockSplits`	1.29M	shares	Annual
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$511.48K	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$283.08K	USD	Annual
Net loss	`NetIncomeLoss`	$-6.55M	USD	Annual
Net loss	`NetIncomeLoss`	$-4.13M	USD	Annual
Ending balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$13.65M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$9.80M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.